Sanofi's Sarclisa rejected by NICE over uncertainties on total benefit, cost-effectiveness

Sanofi
Sanofi's new multiple myeloma med Sarclisa suffered a NICE rejection in draft guidance. (Sanofi)

Sanofi is making a push back into oncology led by multiple myeloma drug Sarclisa, its first wholly-owned cancer medicine in a decade. But now the company’s forthcoming U.K. rollout has hit a snag thanks to cost watchdogs.

In new draft guidance, the National Institute for Health and Care Excellence (NICE) said that just how much benefit Sarclisa provides to patients versus the standard care is unknown, and that cost-effectiveness estimates for the drug are outside of recommended ranges. 

Sanofi’s Sarclisa scored a recommendation from Europe’s Committee for Medicinal Products for Human Use back in March in combo with Bristol Myers Squibb's Pomalyst and dexamethasone (pom-dex) for patients with relapsed and refractory multiple myeloma who have received at least two prior therapies. The European Commission approved the drug last week.

Free Webinar

Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!

For its part, Sanofi is positioning the med as a fourth-line treatment, NICE says, to be used after three prior therapies. As it stands, current fourth-line treatment includes pom-dex alone or Johnson & Johnson’s Darzalex, provided through the Cancer Drugs Fund. 

RELATED: Sanofi's FDA nod for Sarclisa represents a 'return to oncology,' exec says 

Sarclisa delays disease progression and extends patients' lives compared with pom-dex alone, NICE says, but a trial comparing the treatments isn’t finished yet⁠—and that means Sarclisa’s overall benefit is unknown. Plus, cost-effectiveness estimates “are much higher than what NICE normally considers a cost-effective use of NHS resources," the draft guidance said.

The drug’s list price isn’t yet public. NICE's decision isn’t final and is subject to review and consultation. 

Meanwhile, Sanofi's Sarclisa won an FDA approval in March, and it's already chasing another. The drug recently posted positive data in combo with Amgen's Kyprolis, setting it up to potentially challenge Darzalex.

Editor's note: This story was corrected to note that Sarclisa won European approval last week.

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.